These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29422793)

  • 1. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    Intest Res; 2018 Jan; 16(1):4-16. PubMed ID: 29422793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):20-29. PubMed ID: 29023903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):30-36. PubMed ID: 29024102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    Intest Res; 2018 Jan; 16(1):17-25. PubMed ID: 29422794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.
    Ran Z; Wu K; Matsuoka K; Jeen YT; Wei SC; Ahuja V; Chen M; Hu PJ; Andoh A; Kim HJ; Yang SK; Watanabe M; Ng SC; Hibi T; Hilmi IN; Suzuki Y; Han DS; Leung WK; Sollano J; Ooi CJ; Qian J
    J Gastroenterol Hepatol; 2021 Mar; 36(3):637-645. PubMed ID: 32672839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus--Part 1).
    Ooi CJ; Makharia GK; Hilmi I; Gibson PR; Fock KM; Ahuja V; Ling KL; Lim WC; Thia KT; Wei SC; Leung WK; Koh PK; Gearry RB; Goh KL; Ouyang Q; Sollano J; Manatsathit S; de Silva HJ; Rerknimitr R; Pisespongsa P; Abu Hassan MR; Sung J; Hibi T; Boey CC; Moran N; Leong RW;
    J Gastroenterol Hepatol; 2016 Jan; 31(1):45-55. PubMed ID: 25819140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.
    Ooi CJ; Makharia GK; Hilmi I; Gibson PR; Fock KM; Ahuja V; Ling KL; Lim WC; Thia KT; Wei SC; Leung WK; Koh PK; Gearry RB; Goh KL; Ouyang Q; Sollano J; Manatsathit S; de Silva HJ; Rerknimitr R; Pisespongsa P; Abu Hassan MR; Sung J; Hibi T; Boey CC; Moran N; Leong RW;
    J Gastroenterol Hepatol; 2016 Jan; 31(1):56-68. PubMed ID: 25819311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea.
    Lee JY; Oh K; Hong HS; Kim K; Hong SW; Park JH; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Lee HS; Jo KW; Park SH
    BMC Gastroenterol; 2021 Oct; 21(1):390. PubMed ID: 34670529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.
    Nguyen GC; Seow CH; Maxwell C; Huang V; Leung Y; Jones J; Leontiadis GI; Tse F; Mahadevan U; van der Woude CJ; ;
    Gastroenterology; 2016 Mar; 150(3):734-757.e1. PubMed ID: 26688268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
    Ooi CJ; Hilmi I; Banerjee R; Chuah SW; Ng SC; Wei SC; Makharia GK; Pisespongsa P; Chen MH; Ran ZH; Ye BD; Park DI; Ling KL; Ong D; Ahuja V; Goh KL; Sollano J; Lim WC; Leung WK; Ali RAR; Wu DC; Ong E; Mustaffa N; Limsrivilai J; Hisamatsu T; Yang SK; Ouyang Q; Geary R; De Silva JH; Rerknimitr R; Simadibrata M; Abdullah M; Leong RW;
    Intest Res; 2019 Jul; 17(3):285-310. PubMed ID: 31146509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.
    Banerjee R; Ali RAR; Wei SC; Adsul S
    Gut Liver; 2020 Nov; 14(6):685-698. PubMed ID: 33191310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
    Ooi CJ; Hilmi I; Banerjee R; Chuah SW; Ng SC; Wei SC; Makharia GK; Pisespongsa P; Chen MH; Ran ZH; Ye BD; Park DI; Ling KL; Ong D; Ahuja V; Goh KL; Sollano J; Lim WC; Leung WK; Ali RAR; Wu DC; Ong E; Mustaffa N; Limsrivilai J; Hisamatsu T; Yang SK; Ouyang Q; Geary R; De Silva JH; Rerknimitr R; Simadibrata M; Abdullah M; Leong RWL;
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1296-1315. PubMed ID: 30848854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.
    Lee JW; Choi CH; Park JH; Kim JW; Kang SB; Koo JS; Kim YH; Kim YS; Joo YE; Chang SK
    Intest Res; 2016 Apr; 14(2):146-51. PubMed ID: 27175115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID).
    Lee KM; Kim YS; Seo GS; Kim TO; Yang SK;
    Intest Res; 2015 Jul; 13(3):193-207. PubMed ID: 26130993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
    Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
    J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.
    Song EM; Na SY; Hong SN; Ng SC; Hisamatsu T; Ye BD
    Intest Res; 2023 Jul; 21(3):339-352. PubMed ID: 37533265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.